Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842756 | 0.86 | SMN1; SMN2 (0.55) | CRHR1ALDH1A1MAPK1SMN1; SMN2POLB | |
| SCHEMBL6794273 | 0.85 | POLB (0.56) | CRHR1ALDH1A1MAPK1SMN1; SMN2POLB | |
| SCHEMBL5844156 | 0.82 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL5599406 | 0.79 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL5842983 | 0.79 | CRHR1 (0.47) | CRHR1LMNA | |
| SCHEMBL6804578 | 0.78 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL6797027 | 0.78 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL6798443 | 0.78 | CRHR1 (0.57) | CRHR1HPGDCYP3A4 | |
| SCHEMBL5843790 | 0.78 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL6796886 | 0.78 | GAA (0.41) | CRHR1ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125880-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7067664-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-6956047-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-6844351-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0764166-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER (US) | 2000-09-13 | — | — | EP | disclosed |
| US-5962479-A | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0764166-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995033750-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885ALDH1A1 4505/4885MAPK1 1208/4885 |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885ALDH1A1 4423/4885MAPK1 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.